DE69629591D1 - Formulierung zur intranasalen verabreichung - Google Patents

Formulierung zur intranasalen verabreichung

Info

Publication number
DE69629591D1
DE69629591D1 DE69629591T DE69629591T DE69629591D1 DE 69629591 D1 DE69629591 D1 DE 69629591D1 DE 69629591 T DE69629591 T DE 69629591T DE 69629591 T DE69629591 T DE 69629591T DE 69629591 D1 DE69629591 D1 DE 69629591D1
Authority
DE
Germany
Prior art keywords
analgesic
formulation
tramadol
intranasal administration
intranasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69629591T
Other languages
English (en)
Other versions
DE69629591T2 (de
Inventor
Mark Alfonso
Paul Goldenheim
Richard Sackler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of DE69629591D1 publication Critical patent/DE69629591D1/de
Publication of DE69629591T2 publication Critical patent/DE69629591T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
DE69629591T 1995-11-14 1996-11-14 Formulierung zur intranasalen verabreichung Expired - Lifetime DE69629591T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/557,279 US6017963A (en) 1995-11-14 1995-11-14 Formulation for intranasal administration
US557279 1995-11-14
PCT/US1996/018904 WO1997017948A1 (en) 1995-11-14 1996-11-14 Formulation for respiratory tract administration

Publications (2)

Publication Number Publication Date
DE69629591D1 true DE69629591D1 (de) 2003-09-25
DE69629591T2 DE69629591T2 (de) 2004-07-01

Family

ID=24224765

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69629591T Expired - Lifetime DE69629591T2 (de) 1995-11-14 1996-11-14 Formulierung zur intranasalen verabreichung

Country Status (8)

Country Link
US (3) US6017963A (de)
EP (1) EP0877609B1 (de)
JP (1) JP3152437B2 (de)
AT (1) ATE247461T1 (de)
AU (1) AU714303B2 (de)
CA (1) CA2234847C (de)
DE (1) DE69629591T2 (de)
WO (1) WO1997017948A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
WO2000035417A1 (en) * 1998-12-11 2000-06-22 Pharmachemie B.V. Pharmaceutical preparation for inhalation of an opioid
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
ES2427976T5 (es) * 2000-07-31 2022-04-13 Takeda Pharma As Composición de sal de fentanilo para administración nasal
AU2001286518A1 (en) * 2000-08-15 2002-02-25 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
JP2004509920A (ja) * 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ カテコールアミン医薬組成物および方法
DE10049483A1 (de) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte 1-Aminobutan-3-ol-Derivate
US20030053956A1 (en) * 2001-01-24 2003-03-20 Thomas Hofmann Alkylaryl polyether alcohol polymers for treatment and prophylaxis of snoring, sleep apnea, sudden infant death syndrome and for improvement of nasal breathing
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
AU2002252361C1 (en) 2001-03-16 2006-03-30 Aytu Bioscience, Inc. Method of delaying ejaculation
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
WO2002094231A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
KR20050000409A (ko) * 2002-04-25 2005-01-03 브레인스게이트 리미티드 두부 신경에 후각자극제의 신경흥분 및／또는 신경억제효과를 사용함으로써 ｂｂｂ 및 대뇌 순환의 특성을수정하기 위한 방법 및 장치
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
PT1539366E (pt) * 2002-08-06 2009-06-19 Glaxo Group Ltd Dispositivo de distribuição
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
NZ538965A (en) * 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US20040234914A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
SI2486942T1 (sl) 2004-11-24 2019-03-29 Meda Pharmaceuticals Inc. Sestavki, ki obsegajo azelastin, in postopki za njihovo uporabo
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20070111964A1 (en) * 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
CN101325944B (zh) * 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 用于鼻部给药的组合物
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
AU2007208681B2 (en) * 2006-01-27 2010-04-08 Asahi Kasei Pharma Corporation Medicine for transnasal administration
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
US20080262094A1 (en) * 2007-02-12 2008-10-23 Dmi Biosciences, Inc. Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction
NZ579170A (en) 2007-02-12 2012-05-25 Dmi Biosciences Inc Reducing side effects of tramadol
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DK2167069T3 (da) 2007-05-23 2011-11-21 Amcol International Corp Cholesterol-interagerende lagdelte phyllosilikater og fremgangsmåder til at reducere hypercholesterolæmi hos et pattedyr
CA2716835A1 (en) 2008-02-27 2009-09-03 Amcol International Corporation Methods of treating cardiovascular disorders associated with atherosclerosis
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
EP2668945A1 (de) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
CN104208044A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 盐酸曲马多吸入制剂
ES2604816B1 (es) 2015-09-09 2018-01-29 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
EP3668490A4 (de) 2017-08-20 2021-06-09 Formulex Pharma Innovations Ltd. Trockenpulverzusammensetzungen zur intranasalen verabreichung
RU2667808C1 (ru) * 2017-12-19 2018-09-24 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Способ акустико-эмиссионной диагностики ответственных деталей тележек грузовых вагонов при эксплуатации
RU2697159C1 (ru) * 2018-06-18 2019-08-12 Общество с ограниченной ответственностью "МЕЖДУНАРОДНЫЙ ЦЕНТР МОНИТОРИНГА НА ОСНОВЕ ВОЛНОВЫХ ПРОЦЕССОВ" Способ мониторинга технического состояния колес подвижного состава во время движения

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
US4624965A (en) * 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
EP0189861A3 (de) * 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Transdermaler Absorptionsbeschleuniger für ionische wasserlösliche Arzneistoffe
US4729997A (en) * 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
US5066648A (en) * 1985-11-29 1991-11-19 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
DE3602370A1 (de) * 1986-01-27 1987-08-06 Chrubasik Sigrun Verwendung von analgetica durch inhalation
US4778810A (en) * 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4973596A (en) * 1988-05-20 1990-11-27 Barr Laboratories, Inc. Method of administering a narcotic analgesic and dosage forms therefor
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
JP2875611B2 (ja) * 1990-08-29 1999-03-31 エーザイ株式会社 ケイ酸カルシウム含有外用剤
DK0566709T5 (da) * 1991-09-06 2009-05-18 Ortho Mcneil Janssen Pharm Præparat indeholdende et tramadolmateriale og acetaminophen og anvendelse deraf
ATE145330T1 (de) * 1991-09-06 1996-12-15 Mcneilab Inc Zusammensetzungen, die tramadol und irgendein kodein, oxykoden oder hydrokoden enthalten, und deren verwendung
US5223541A (en) * 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
EP0583482B1 (de) 1992-02-07 1999-12-29 Kaken Pharmaceutical Co., Ltd. Heilmittel für wunden und hämorrhoiden
DE4221256C2 (de) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
WO1994004139A1 (en) 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
AU5551394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
JPH06199701A (ja) * 1992-12-29 1994-07-19 Lion Corp 外用消炎鎮痛剤
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
EP0691848A1 (de) 1993-04-07 1996-01-17 Eisai Co., Ltd. Immunverstärkendes und infektionschützendes mittel, das zwei oder mehreren von bacillus, eiweiss und knoblauch enthält
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs

Also Published As

Publication number Publication date
WO1997017948A1 (en) 1997-05-22
CA2234847C (en) 2002-06-25
EP0877609A1 (de) 1998-11-18
EP0877609A4 (de) 2000-06-07
JP3152437B2 (ja) 2001-04-03
US6642275B2 (en) 2003-11-04
US6017963A (en) 2000-01-25
JPH11500148A (ja) 1999-01-06
ATE247461T1 (de) 2003-09-15
CA2234847A1 (en) 1997-05-22
US20020022663A1 (en) 2002-02-21
AU1060497A (en) 1997-06-05
AU714303B2 (en) 1999-12-23
EP0877609B1 (de) 2003-08-20
DE69629591T2 (de) 2004-07-01
US20010049391A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
ATE247461T1 (de) Formulierung zur intranasalen verabreichung
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
ZA968808B (en) Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agoinst and a kappa-2 opioid agonist
SE9503924D0 (sv) Novel opioid peptides
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
UA84277C2 (ru) Композиция трамадола с пролонгированным высвобождением с 24-часовым действием
NO963850D0 (no) Heterosykliske forbindelser, deres fremstilling og anvendelse
DK0606366T3 (da) Substituerede phenseriner og phenylcarbamater af (-)-eserolin, (-)-N1-noreserolin og (-)-N1-benzylnoreserolin som specifikke inhibitorer af acetylcholinesterase
DK1003494T3 (da) (d)-metadon, et ikke-opioidt analgetikum
DK1039900T3 (da) Farmaceutisk præparat indeholdende sibutramin og orlistat
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
TWI319713B (en) Sustained-release tramadol formulations with 24-hour efficacy
HUP9700661A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
YU37001A (sh) Kombinacija lekova analgetika
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
SE9502877D0 (sv) Novel opioid peptides
SE9802555D0 (sv) New pharmaceutical preparation and method
JO2127B1 (en) How to prevent asthma
RS49796B (sr) UPOTREBA SOLI 3α, 7α-DIHIDROKSI-12-KETO-5β-HOLANSKE KISELINE KAO AKTIVNE SUPSTANCE ZA IZRADU LEKOVA ZA LEČENJE DIJABETESA

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: EURO-CELTIQUE S.A., LUXEMBURG/LUXEMBOURG, LU

8364 No opposition during term of opposition